Login / Signup

Sex Differences in Time-Series Changes in Pseudo-R2 Values Regarding Hyperuricemia in Relation to the Kidney Prognosis.

Hiroshi KataokaMamiko OharaToshio MochizukiKazuhiro IwadohYusuke UshioKeiko KawachiKentaro WatanabeSaki WatanabeTaro AkihisaShiho MakabeShun ManabeMasayo SatoNaomi IwasaRie YoshidaYukako SawaraNorio HanafusaKen TsuchiyaKosaku Nitta
Published in: Journal of personalized medicine (2020)
Studies on sex differences in time-series changes in pseudo-R2 values regarding hyperuricemia (HU) in relation to the kidney prognosis among patients with chronic kidney disease (CKD) are scant. The kidney prognosis was evaluated in 200 patients with CKD (median follow-up, 12.3 years). Survival analyses and logistic regression analyses were conducted, generating time-series pseudo-R2 values. We used four definitions of HU according to serum uric acid (SUA) levels (HU6, SUA ≥ 6.0 mg/dL; HU7, SUA ≥ 7.0 mg/dL; HU8, SUA ≥ 8.0 mg/dL) and antihyperuricemic agent use to calculate the mean and percentage of the change in pseudo-R2 values from the 6th year until the end of the study (6Y-End Mean and 6Y-End Change, respectively). The multivariable Cox regression analysis showed that HU7 was significantly associated with kidney outcomes. When stratified by sex, the 6Y-End Mean was clearly higher in women than in men for all HU definitions, with the highest value (0.1755) obtained for HU7 in women. The pseudo-R2 values for HU6 in women showed an increasing pattern, with a 6Y-End Change of 11.4%/year. Thus, it may be clinically meaningful to consider sex differences in the time-series pseudo-R2 values regarding HU and kidney outcomes.
Keyphrases
  • uric acid
  • polycystic ovary syndrome
  • chronic kidney disease
  • metabolic syndrome
  • type diabetes
  • pregnant women
  • insulin resistance
  • cervical cancer screening